Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
152.72
+1.12 (0.74%)
Sep 17, 2025, 4:00 PM EDT - Market closed
CRL Revenue
Charles River Laboratories International had revenue of $1.03B in the quarter ending June 28, 2025, with 0.59% growth. This brings the company's revenue in the last twelve months to $4.03B, down -1.21% year-over-year. In the year 2024, Charles River Laboratories International had annual revenue of $4.05B, down -1.92%.
Revenue (ttm)
$4.03B
Revenue Growth
-1.21%
P/S Ratio
1.92
Revenue / Employee
$200,429
Employees
20,100
Market Cap
7.52B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 28, 2024 | 4.05B | -79.42M | -1.92% |
Dec 30, 2023 | 4.13B | 153.35M | 3.86% |
Dec 31, 2022 | 3.98B | 435.90M | 12.31% |
Dec 25, 2021 | 3.54B | 616.23M | 21.08% |
Dec 26, 2020 | 2.92B | 302.71M | 11.55% |
Dec 28, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 29, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 26, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CRL News
- 1 day ago - Charles River Laboratories Announces Chief Financial Officer Transition - Business Wire
- 6 days ago - Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer - Business Wire
- 7 days ago - Charles River Laboratories International, Inc. (CRL) Presents At Baird 2025 Global Healthcare Conference (Transcript) - Seeking Alpha
- 8 days ago - Charles River Laboratories International, Inc. (CRL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 9 days ago - Charles River Laboratories to Present at Baird and Morgan Stanley Conferences - Business Wire
- 14 days ago - Charles River Enhances Cell Therapy Flex Platform through Collaboration with Akadeum Life Sciences - Business Wire
- 22 days ago - Charles River Joins EASYGEN Consortium, Supports Development of Bedside CAR-T Manufacturing - Business Wire
- 6 weeks ago - Charles River Laboratories International, Inc. (CRL) Q2 2025 Earnings Call Transcript - Seeking Alpha